Skandinaviska Enskilda Banken (SEB)
LENZ

Skandinaviska Enskilda Banken (SEB)’s LENZ Therapeutics LENZ Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-185,642
Closed -$2.97M – 724
2025
Q4 		$2.97M Hold
185,642
– – 0.01% 511
2025
Q3 		$8.65M Buy
185,642
+92,362
+99% +$3.4M 0.03% 311
2025
Q2 		$2.73M Buy
+93,280
New +$2.54M 0.01% 526

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s LENZ Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 185,642 shares — an estimated $2.97M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in LENZ in Q2 2025 and held it in 3 quarters. The position peaked at $8.65M in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 185,642 LENZ Therapeutics shares in Q1 2026, an estimated $2.97M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in LENZ Therapeutics in Q2 2025 and held it in 3 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s LENZ Therapeutics position peaked at $8.65M in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.